Shionogi EPS - Earnings per Share 2021-2023 | SGIOY

Shionogi earnings per share (EPS) for the twelve months ending December 31, 2023 was $0.49, a 80% increase year-over-year.

  • Shionogi EPS for the quarter ending December 31, 2023 was $0.00, a 100% decline year-over-year.
  • Shionogi 2024 annual EPS was $0.64, a 16.19% decline from 2023.
  • Shionogi 2023 annual EPS was $0.77, a 36.3% increase from 2022.
  • Shionogi 2022 annual EPS was $0.56, a 1.75% decline from 2021.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.

Shionogi EPS - Earnings per Share 2021-2023 | SGIOY

  • Shionogi EPS for the quarter ending December 31, 2023 was $0.00, a 100% decline year-over-year.
  • Shionogi 2024 annual EPS was $0.64, a 16.19% decline from 2023.
  • Shionogi 2023 annual EPS was $0.77, a 36.3% increase from 2022.
  • Shionogi 2022 annual EPS was $0.56, a 1.75% decline from 2021.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$78.6B
Takeda Pharmaceutical (TAK)$44.1B
Merck (MKKGY)$21.2B
Astellas Pharma (ALPMY)$20.4B
Sandoz Group AG (SDZNY)$19.7B
United Therapeutics (UTHR)$18B
Summit Therapeutics (SMMT)$15.6B
Neurocrine Biosciences (NBIX)$12.6B
Catalent (CTLT)$10.9B
Madrigal Pharmaceuticals (MDGL)$7.7B
Jazz Pharmaceuticals (JAZZ)$7.4B
Orion OYJ (ORINY)$6.8B
Ionis Pharmaceuticals (IONS)$6.1B
Corcept Therapeutics (CORT)$5.7B
Crinetics Pharmaceuticals (CRNX)$4.8B
PTC Therapeutics (PTCT)$3.3B
Dyne Therapeutics (DYN)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.7B
Soleno Therapeutics (SLNO)$2.5B
NewAmsterdam Pharma (NAMS)$2B
Recursion Pharmaceuticals (RXRX)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Harrow (HROW)$1.8B
Ocular Therapeutix (OCUL)$1.7B
Xencor (XNCR)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
ARS Pharmaceuticals (SPRY)$1.6B
Avadel Pharmaceuticals (AVDL)$1.5B